About ovid therapeutics inc - OVID
Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.
OVID At a Glance
Ovid Therapeutics, Inc.
441 9th Avenue
New York, New York 10001
| Phone | 1-646-661-7661 | Revenue | 7.25M | |
| Industry | Pharmaceuticals: Major | Net Income | -17,414,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 1,181.272% | |
| Fiscal Year-end | 12 / 2026 | Employees | 23 | |
| View SEC Filings |
OVID Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.573 |
| Price to Book Ratio | 1.624 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.518 |
| Enterprise Value to Sales | 8.821 |
| Total Debt to Enterprise Value | 0.21 |
OVID Efficiency
| Revenue/Employee | 315,304.348 |
| Income Per Employee | -757,130.435 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.06 |
OVID Liquidity
| Current Ratio | 8.973 |
| Quick Ratio | 8.973 |
| Cash Ratio | 8.402 |
OVID Profitability
| Gross Margin | 95.863 |
| Operating Margin | -585.204 |
| Pretax Margin | -240.127 |
| Net Margin | -240.127 |
| Return on Assets | -14.327 |
| Return on Equity | -17.512 |
| Return on Total Capital | -12.086 |
| Return on Invested Capital | -15.528 |
OVID Capital Structure
| Total Debt to Total Equity | 10.27 |
| Total Debt to Total Capital | 9.314 |
| Total Debt to Total Assets | 8.891 |
| Long-Term Debt to Equity | 9.173 |
| Long-Term Debt to Total Capital | 8.319 |